Current Clinical Trials at Ballad Health

Groundbreaking research close to home

Ballad Health has brought together a team of innovative physicians and clinicians who are at the forefront of leading-edge research and clinical trials.

We're a consistent leader in clinical research, and we're leveraging that track record to better improve healthcare across the region.

View Ballad Health's current clinical trials

See Active Trials

What are clinical trials?

Clinical trials can be defined in a number of ways, but they typically involve studies to evaluate the effectiveness of new drugs and treatments.

The data from these trials helps us understand what approach will work best for all Ballad Health patients moving forward.

Benefits of clinical trial participation

Research and trials often lead to new approaches in diagnosing, preventing and treating conditions ranging from heart disease to cancer. This is especially important in fields such as cardiology, oncology and hematology.

Our team is driven to ensure our communities across the region have access to advanced treatment options. In the past, many people in the Appalachian Highlands community had to travel to large teaching hospitals for the latest in drugs and tech. By extending studies to our community, patients now have a choice of staying closer to home when joining a clinical trial.

Participants in local clinical trials can typically play a more active role in their own healthcare, gaining access to new research and treatments before they're available – leaving a legacy that benefits all future patients.

Consider your trial options early

You should work with your doctor to decide as early in your evaluation as possible whether participating in a clinical trial is an appropriate treatment option for you. Once other treatments begin, you may become ineligible to participate in some clinical trials.

Your safety and privacy are our top priority

To ensure safety for all our patients, every study is reviewed and approved by an Institutional Review Board, the director of research and a clinical research committee.

Our patients are monitored carefully throughout every clinical trial. Special care is always taken to help you understand any study that you participate in so you can be an active participant in your own treatment.

All patient information regarding clinical trials is kept confidential.

How to participate in a clinical trial

If you're approached about participating in a trial or have expressed interest in joining a trial, listen carefully and always discuss it with your family and doctor.

Volunteering for any study is a choice only you can make.

If you're interested in possible trials or research studies, you can speak to your physician or contact our research team for more details and information at clinicaltrials@balladhealth.org or by calling (423) 230-5615.

Current active clinical trials at Ballad Health

Click on your preferred specialty to see the list of active or ongoing trials offered at Ballad Health facilities.

Evaluation in STEMI Patients Using FDY-5301 (IOCYTE AMI-3)

Locations: Ballad Health CVA Heart Institute (Johnson City), Johnson City Medical Center

Principal investigator (PI): Jack Whitaker, MD

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function (PROTECT IV)

Location: Holston Valley Medical Center

Post-Approval Study of the TREO Abdominal Stent-Graft System (TREO PAS)

Locations: CVA Heart Institute (Kingsport, Johnson City)

Principal investigators (PIs): Robert Allen, MD (Kingsport); Richard Yoon, MD (Johnson City)

Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial (DTU-STEMI)

Locations: Holston Valley Medical Center

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Location: Greeneville Community Hospital

Principal investigator (PI): Jack Whitaker, MD

Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (HI-PEITHO)

Location: Holston Valley Medical Center

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS)

Location: Greeneville Community Hospital

Principal investigator (PI): Jack Whitaker, MD

Cepheid AML NPM1 Mutation Test

The purpose of this collection is for the acquisition of EDTA peripheral blood (PB) specimens from patients who (i) have been diagnosed with NPM1-mutated AML and (ii) are being monitored for NPM1 mutation. Consists of 3 visits.

Location: Regional Cancer Center (Johnson City)

Principal investigator (PI): Devapiran Jaishankar, MD

SeraTrials

Consists of a single clinical research sample collection. Cord blood and cancer targeted samples will change periodically based on sponsor’s need.

Locations: Indian Path Community Hospital, Bristol Regional Medical Center, Regional Cancer Center (Johnson City), Johnson City Medical Center, Franklin Woods Community Hospital, Sycamore Shoals Hospital

Principal investigator (PI): Matthew Loos, MD

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Location: Ballad Health Cancer Center (Kingsport)

Principal investigators (PIs): Scott Coen, MD; Paul Kramer, MD

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. (VOICE)

Locations: Johnson City Medical Center

Principal investigator (PI): Kyle Colvett, MD

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Comparing the New Anti-cancer Drug Eribulin With or Without Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer (MRD)

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Enhancing Cancer Care of Rural Dwellers Through Telehealth and Engagement (ENCORE)

Available for newly diagnosed or relapsed patients. Requires access to reliable video capable device with internet. A device and/or data plan can be provided to patients who need it.

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses (CREDIT)

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Location: Ballad Health Cancer Center (Kingsport)

Principal investigators (PIs): Paul Kramer, MD; Jamal Maatouk, MD; Ibrahim Nakkoul, MD; Yonette Paul, MD; Asheesh Shipstone, MD; Marco Da Silva, MD

Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Locations: Ballad Health Cancer Center (Kingsport, Norton)

Principal investigators (PIs): Scott Coen, MD (Kingsport); Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have Symptoms, the EVOLVE CLL/SLL Study

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer (SOLARIS)

Locations: Ballad Health Cancer Center (Kingsport, Bristol, Norton)

Principal investigators (PIs): Paul Kramer, MD (Kingsport); Jamal Maatouk, MD (Kingsport); Harish Madala, MD (Norton); Tamara Musgrave, MD (Bristol); Ibrahim Nakkoul, MD (Kingsport); Yonette Paul, MD (Kingsport); Ryan Shao, MD (Bristol); Asheesh Shipstone, MD (Kingsport); Marco Da Silva, MD (Kingsport)

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) (ReMEDy2)

Location: Johnson City Medical Center

Principal investigator (PI): Tanzid Shams, MD

Contact us

If you have questions about any of our active trials, you can reach out to us by emailing clinicaltrials@balladhealth.org or calling (423) 230-5615.

Cookies UI